Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Symbol: 002399.SZ
SHZ
9.37
CNYDzisiejsza cena rynkowa
-17.2720
Wskaźnik P/E
-0.4195
Wskaźnik PEG
12.33B
Kapitalizacja MRK
- 0.01%
Rentowność DIV
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399-SZ) Sprawozdania finansowe
Bilans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 10139.37 | 2265.8 | 3450.4 | 3925.4 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 1631.92 | 414.2 | 1311.6 | 981.2 | ||||||||||||||||||
balance-sheet.row.net-receivables | 6253.86 | 1528.6 | 1946.6 | 1985.5 | ||||||||||||||||||
balance-sheet.row.inventory | 30150.6 | 6654.1 | 6843.9 | 4707.5 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 857.6 | 155.4 | 148.7 | 151.2 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 47401.43 | 10603.9 | 12389.6 | 10769.7 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 10261.67 | 2634.2 | 2477.3 | 2537.2 | ||||||||||||||||||
balance-sheet.row.goodwill | 9504.81 | 2322.4 | 2351 | 2152.2 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 2153.33 | 493.2 | 571.7 | 586.7 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 11658.14 | 2815.6 | 2922.6 | 2738.9 | ||||||||||||||||||
balance-sheet.row.long-term-investments | 8198.95 | 2514.9 | 1152.5 | 1636.7 | ||||||||||||||||||
balance-sheet.row.tax-assets | 753.39 | 320.5 | 139.6 | 121.7 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 2460.85 | 314.3 | 1732.5 | 1304.1 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 33333 | 8599.5 | 8424.6 | 8338.5 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 80734.43 | 19203.4 | 20814.2 | 19108.2 | ||||||||||||||||||
balance-sheet.row.account-payables | 1374.71 | 302.2 | 427.4 | 385.8 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 14923.61 | 3662.4 | 4056.5 | 3299.9 | ||||||||||||||||||
balance-sheet.row.tax-payables | 525.27 | 157.2 | 141.8 | 158.7 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 8990.3 | 1810 | 2407.4 | 2354.3 | ||||||||||||||||||
Deferred Revenue Non Current | 127.65 | 30.4 | 32.5 | 16.7 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1232.54 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | 3123.05 | 655.4 | 658 | 3.8 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 10620.06 | 2198 | 2830.8 | 2793.4 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 383.85 | 90.4 | 110.7 | 104 | ||||||||||||||||||
balance-sheet.row.total-liab | 31250.86 | 7184.2 | 8406.6 | 7584.9 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 5869.18 | 1467.3 | 1467.3 | 1467.3 | ||||||||||||||||||
balance-sheet.row.retained-earnings | 14530.6 | 1543.2 | 4314.1 | 3647 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 9077.94 | 1373.8 | 843.4 | 563.9 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 19614.97 | 7528.9 | 5686.1 | 5733.2 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 49092.69 | 11913.1 | 12310.9 | 11411.4 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 80734.43 | 19203.4 | 20814.2 | 19108.2 | ||||||||||||||||||
balance-sheet.row.minority-interest | 360.05 | 75.2 | 96.7 | 112 | ||||||||||||||||||
balance-sheet.row.total-equity | 49452.73 | 11988.4 | 12407.6 | 11523.3 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 80734.43 | - | - | - | ||||||||||||||||||
Total Investments | 9830.87 | 2929.1 | 2464.1 | 2617.8 | ||||||||||||||||||
balance-sheet.row.total-debt | 24004.33 | 5562.8 | 6463.9 | 5654.2 | ||||||||||||||||||
balance-sheet.row.net-debt | 15496.87 | 3711.2 | 4325.1 | 2709.9 |
Rachunek przepływów pieniężnych
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -783.26 | -783.3 | 714.7 | 233.4 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 371.05 | 384.7 | 307.7 | 302.7 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | 3.98 | -237.6 | -43.3 | -170.6 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | -1332.4 | 43.3 | 0.2 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | -349.12 | -563.1 | -2311.3 | -1125.1 | ||||||||||||||||||
cash-flows.row.account-receivables | 270.55 | 270.5 | -176.1 | 141.8 | ||||||||||||||||||
cash-flows.row.inventory | -619.67 | -619.7 | -2151.6 | -1520.2 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | -213.9 | 59.7 | 423.9 | ||||||||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | -43.3 | -170.6 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 548.74 | 3003.1 | 532.3 | 752.7 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 678.73 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -444.88 | -444.9 | -222.4 | -193.9 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 2.34 | -4.9 | 0 | 1.7 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | -677.26 | -758.2 | -4482.7 | -2370.2 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 1647.35 | 2349.3 | 4210.7 | 3305.1 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 694.02 | -0.1 | 744.2 | -22.9 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 1221.57 | 1141.2 | 249.8 | 719.9 | ||||||||||||||||||
cash-flows.row.debt-repayment | -5991.71 | -730.9 | -6036.3 | -3730.6 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | -425.89 | -146.7 | -251 | -412.5 | ||||||||||||||||||
cash-flows.row.other-financing-activites | 5207.43 | -325.4 | 6616.8 | 3642 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -1210.17 | -1203 | 329.6 | -501.1 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 36.32 | 36.3 | 17.3 | -62.8 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | 445.94 | -287.1 | -159.9 | 149.4 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 6714.63 | 1851.6 | 1319.7 | 1479.6 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 6268.69 | 2138.8 | 1479.6 | 1330.2 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 678.73 | 471.4 | -756.6 | -6.6 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -444.88 | -444.9 | -222.4 | -193.9 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 233.86 | 26.5 | -979 | -200.5 |
Wiersz rachunku zysków i strat
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 5434.47 | 5421.7 | 7159.4 | 6365.2 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 3670.52 | 3746.3 | 4825 | 4332.1 | ||||||||||||||||||
income-statement-row.row.gross-profit | 1763.95 | 1675.4 | 2334.4 | 2033 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 179.91 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 458.57 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 517.42 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | -985.68 | -855.4 | 294.7 | 274.9 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 2128.44 | 1935.4 | 1211.9 | 1068.9 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 5798.96 | 5681.6 | 6036.9 | 5401 | ||||||||||||||||||
income-statement-row.row.interest-income | -39.52 | -39.5 | 54.1 | 54.9 | ||||||||||||||||||
income-statement-row.row.interest-expense | 223.22 | 223.2 | 235.2 | 201.6 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 517.42 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -89.2 | -220.4 | -305.3 | -550.9 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | -985.68 | -855.4 | 294.7 | 274.9 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | -89.2 | -220.4 | -305.3 | -550.9 | ||||||||||||||||||
income-statement-row.row.interest-expense | 223.22 | 223.2 | 235.2 | 201.6 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 241.34 | 384.7 | 307.7 | 302.7 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | -433.09 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | -674.43 | -259.9 | 1135.1 | 773.2 | ||||||||||||||||||
income-statement-row.row.income-before-tax | -763.62 | -480.4 | 829.9 | 222.3 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | -126.17 | -126.2 | 115.2 | -11.1 | ||||||||||||||||||
income-statement-row.row.net-income | -783.26 | -783.3 | 727.4 | 240.8 |
Często zadawane pytania
Ile wynosi Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) aktywów ogółem?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) całkowite aktywa to 19203415131.000.
Jaki jest roczny przychód przedsiębiorstwa?
Roczny przychód to 2721572551.000.
Jaka jest marża zysku firmy?
Marża zysku firmy to 0.325.
Czym są wolne przepływy pieniężne firmy?
Wolne przepływy pieniężne to 0.159.
Jaka jest marża zysku netto przedsiębiorstwa?
Marża zysku netto to -0.144.
Jaki jest całkowity przychód firmy?
Całkowity przychód to -0.124.
Co to jest Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) zysk netto (dochód netto)?
Zysk netto (dochód netto) wynosi -783258039.000.
Jakie jest całkowite zadłużenie firmy?
Całkowite zadłużenie to 5562816036.000.
Ile wynoszą koszty operacyjne?
Wydatki operacyjne to 1935358054.000.
Jaka jest wartość gotówki firmy?
Środki pieniężne przedsiębiorstwa to 1851642224.000.